Home » Stocks » ASMB

Assembly Biosciences, Inc. (ASMB)

Stock Price: $6.13 USD -0.09 (-1.45%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $6.14 +0.01 (0.16%) Jan 15, 7:36 PM
Market Cap 202.43M
Revenue (ttm) 82.83M
Net Income (ttm) -49.82M
Shares Out 35.51M
EPS (ttm) -1.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $6.13
Previous Close $6.22
Change ($) -0.09
Change (%) -1.45%
Day's Open 6.23
Day's Range 6.10 - 6.34
Day's Volume 614,123
52-Week Range 4.87 - 27.04

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 month ago

Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting he...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting he...

GlobeNewsWire - 1 month ago

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusi...

GlobeNewsWire - 2 months ago

- Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV preg e n o mic ( pg ) RNA as a key biomarker , as well as highlight Assembly Bio's core inhibitor...

The Motley Fool - 2 months ago

The clinical-stage biotech had a big pipeline setback.

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting he...

InvestorPlace - 2 months ago

Assembly Biosciences (ASMB) news for Friday includes clinical trial information from its third quarter of 2020 dropping ASMB stock. The post Assembly Biosciences News: Why ASMB Stock Is Plungi...

Zacks Investment Research - 2 months ago

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 88.46% and 437.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for...

GlobeNewsWire - 2 months ago

- HBV field's first c ore i nhibitor combination study to assess off-treatment response has not achieve d a meaningful rate of sustained virologic response -  - Vebicorvir Phase 3 registration...

Zacks Investment Research - 2 months ago

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 2 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting he...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting he...

GlobeNewsWire - 3 months ago

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting he...

GlobeNewsWire - 4 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting ...

Zacks Investment Research - 5 months ago

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 733.33% and 28.92%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the ...

GlobeNewsWire - 5 months ago

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting ...

Zacks Investment Research - 5 months ago

Assembly Biosciences (ASMB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

-- BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China -- -- Assembly receives $40 million upfront payment and is eligible to r...

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting ...

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting ...

Zacks Investment Research - 6 months ago

Assembly Biosciences (ASMB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 6 months ago

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting ...

GlobeNewsWire - 6 months ago

-- Process to explore strategic alternatives underway -- SOUTH SAN FRANCISCO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechn...

Zacks Investment Research - 8 months ago

Assembly Biosciences (ASMB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

As of late, it has definitely been a great time to be an investor Assembly Biosciences

Seeking Alpha - 8 months ago

Assembly Biosciences, Inc. (ASMB) Assembly Biosciences' HBV Portfolio Progress Conference Call (Transcript)

GlobeNewsWire - 9 months ago

SOUTH SAN FRANCISCO, Calif., March 31, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...

Zacks Investment Research - 10 months ago

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.98% and 27.73%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for th...

Zacks Investment Research - 10 months ago

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced the closing of its previously announced underwritten pu...

The Motley Fool - 1 year ago

An enthusiastic price for a secondary share offering lifted spirits and the stock.

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced the pricing of an underwritten public offering of 5,151...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced that it intends to offer and sell, subject to market an...

Investors Business Daily - 1 year ago

A Relative Strength Rating upgrade for Assembly Biosciences shows improving technical performance.

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting ...

The Motley Fool - 1 year ago

Arrowhead Pharmaceuticals and Assembly Biosciences headed into an important industry meeting with rising share prices. Only one left the meeting with momentum intact.

Other stocks mentioned: ARWR
GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting ...

Zacks Investment Research - 1 year ago

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting ...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting ...

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting ...

The Motley Fool - 1 year ago

Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.

Other stocks mentioned: CBAY, MDGL
Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for October 18th

Other stocks mentioned: BCC, CDNA, DOOO
The Motley Fool - 1 year ago

Investors digesting a late-breaking data drop pushed up the stock.

Investors Business Daily - 1 year ago

Shares of Assembly Biosciences rocketed in higher-than-average volume for a second day Thursday on excitement surrounding the biotech company's potential hepatitis B treatment.

The Motley Fool - 1 year ago

The company reported promising updates for two important pipeline programs.

GlobeNewsWire - 1 year ago

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting ...

Zacks Investment Research - 1 year ago

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 1.87% and 1.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the st...

About ASMB

Assembly Biosciences operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes ... [Read more...]

Industry
Biotechnology
IPO Date
Dec 17, 2010
CEO
Dr. John G. McHutchison A.O., M.D., FRACP
Employees
140
Stock Exchange
NASDAQ
Ticker Symbol
ASMB
Full Company Profile

Financial Performance

In 2019, ASMB's revenue was $15.96 million, an increase of 7.83% compared to the previous year's $14.80 million. Losses were -$97.63 million, 7.58% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for ASMB stock is "Strong Buy." The 12-month stock price forecast is 18.60, which is an increase of 203.43% from the latest price.

Price Target
$18.60
(203.43% upside)
Analyst Consensus: Strong Buy